Per the WHO, a diagnosis of AML may be made for certain abnormalities irrespective of blast percent; these include PML::RARA, AML with RUNX1::RUNX1T1 and AML with CBF::MYH11, in addition to mutations in NPM1 and biallelic (biCEBPA) or single mutations located in the basic leucine zipper (bZIP) region of the gene (smbZIP-CEBPA). This evidence concerns the gene PML and acute myeloid leukemia.